2020-04-28FDA approves new dosing regimen for pembrolizumabTrial KEYNOTE-555Drugs KEYTRUDA (400 mg every six weeks for pembrolizumab) , KEYTRUDA (pembrolizumab) · Anti-PD-1 antibodyConditionOther